相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Simultaneous analysis of drugs administered to lung-transplanted patients using liquid chromatography-tandem mass spectrometry for therapeutic drug monitoring
Shinya Takasaki et al.
BIOMEDICAL CHROMATOGRAPHY (2021)
Pharmacokinetic study of lenvatinib in Chinese patients with solid tumors
Dan Liu et al.
FUTURE ONCOLOGY (2021)
Differential adsorption of an analyte and its D4, D5 and 13C6 labeled analogues combined with instrument-specific carry-over issues: The Achilles' heel of ibrutinib TDM
Martin Mzik et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2021)
Development of a simultaneous analytical method for clozapine and its metabolites in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry with linear range adjusted by in-source collision-induced dissociation
Toshihiro Sato et al.
BIOMEDICAL CHROMATOGRAPHY (2021)
Absolute quantitative analysis of endogenous neurotransmitters and amino acids by liquid chromatography-tandem mass spectrometry combined with multidimensional adsorption and collision energy defect
Jiajia Shen et al.
JOURNAL OF CHROMATOGRAPHY A (2021)
High-throughput liquid chromatography/electrospray ionization-tandem mass spectrometry method using in-source collision-induced dissociation for simultaneous quantification of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in human plasma
Tensei Hirasawa et al.
BIOMEDICAL CHROMATOGRAPHY (2021)
Establishment of an analytical method for simultaneous quantitation of CDK4/6 inhibitors, aromatase inhibitors, and an estrogen receptor antagonist in human plasma using LC-ESI-MS/MS
Yu Sato et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2021)
EGFR activation limits the response of liver cancer to lenvatinib
Haojie Jin et al.
NATURE (2021)
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Lei Zhong et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Pharmacokinetics of Nilotinib in Pediatric Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia or Acute Lymphoblastic Leukemia
Nobuko Hijiya et al.
CLINICAL CANCER RESEARCH (2020)
Validation of an analytical method using HPLC-MS/MS to quantify osimertinib in human plasma and supplementary stability results
Ard van Veelen et al.
BIOMEDICAL CHROMATOGRAPHY (2020)
Novel high-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification of BCR-ABL and Bruton's tyrosine kinase inhibitors and their three active metabolites in human plasma
Yuji Mukai et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2020)
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
Lecia Sequist et al.
LANCET ONCOLOGY (2020)
Effective quantification of 11 tyrosine kinase inhibitors and caffeine in human plasma by validated LC-MS/MS method with potent phospholipids clean-up procedure. Application to therapeutic drug monitoring
Dora Koller et al.
TALANTA (2020)
Pharmacokinetics of dasatinib in a hemodialysis patient with chronic myeloid leukemia and chronic kidney disease
Jinichi Mori et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2020)
Analysis of Complexation Interactions between Metal Ions and Drugs under Pseudo-physiological pH Conditions by a High-throughput Screening Method Using a Solid-phase Extraction Cartridge
Yukiko Moriiwa et al.
ANALYTICAL SCIENCES (2020)
Population pharmacokinetics-pharmacodynamics of sunitinib in pediatric patients with solid tumors
Erjian Wang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)
Quantification of afatinib, alectinib, crizotinib and osimertinib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry; focusing on the stability of osimertinib
G. D. Marijn Veerman et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2019)
Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine
Stefanie L. Groenland et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Fundamental Study of Behaviors of In-Source Collision Induced Dissociation and Shifting the Linear Range of Calibration Curves of Various Drugs and the Metabolites Used for Therapeutic Drug Monitoring
Masamitsu Maekawa et al.
CHROMATOGRAPHY (2019)
Efficacy, Safety, and Pharmacokinetics of Axitinib in Nasopharyngeal Carcinoma: A Preclinical and Phase II Correlative Study
Edwin P. Hui et al.
CLINICAL CANCER RESEARCH (2018)
High throughput routine determination of 17 tyrosine kinase inhibitors by LC-MS/MS
Camille Merienne et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2018)
Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients
Rafael Reis et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2018)
Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
Remy B. Verheijen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing
Remy B. Verheijen et al.
CLINICAL PHARMACOKINETICS (2017)
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G. V. Long et al.
ANNALS OF ONCOLOGY (2017)
Ibrutinib for treatment of chronic lymphocytic leukemia
Cory M. Vela et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2016)
A simultaneous determination method for 5-fluorouracil and its metabolites in human plasma with linear range adjusted by in-source collision-induced dissociation using hydrophilic interaction liquid chromatography-electrospray ionization-tandem mass spectrometry
Hideaki Ishii et al.
BIOMEDICAL CHROMATOGRAPHY (2016)
LC-MS/MS as a tool for TDM services: Where are we?
Maria Shipkova et al.
CLINICAL BIOCHEMISTRY (2016)
Association of variations in HLA class II and other loci with susceptibility to EGFR-mutated lung adenocarcinoma
Kouya Shiraishi et al.
NATURE COMMUNICATIONS (2016)
Review of therapeutic drug monitoring of anticancer drugs part two - Targeted therapies
Nicolas Widmer et al.
EUROPEAN JOURNAL OF CANCER (2014)
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Mark G. Kris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Evidence for Therapeutic Drug Monitoring of Targeted Anticancer Therapies
Bo Gao et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Phase III Trial
Giorgio V. Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Population pharmacokinetic analysis of sorafenib in patients with solid tumours
Lokesh Jain et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer
David R. Spigel et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Expanding the linear dynamic range for multiple reaction monitoring in quantitative liquid chromatography-tandem mass spectrometry utilizing natural isotopologue transitions
Hanghui Liu et al.
TALANTA (2011)
Correlation Between Imatinib Pharmacokinetics and Clinical Response in Japanese Patients With Chronic-Phase Chronic Myeloid Leukemia
N. Takahashi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia
Stephane Picard et al.
BLOOD (2007)
Metabolism and disposition of imatinib mesylate in healthy volunteers
HP Gschwind et al.
DRUG METABOLISM AND DISPOSITION (2005)
Expanding the linear dynamic range in quantitative high performance liquid chromatography/tandem mass spectrometry by the use of multiple product ions
MA Curtis et al.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2001)